drugset / Trial / NCT03187015

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

NCT03187015

Phase 1 Completed 26 enrolled Syndax Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of Entinostat on the bioavailability of Midazolam. The primary objective is to evaluate the effect of a single oral dose of entinostat on the pharmacokinetics (PK) of a single oral dose of midazolam in healthy subjects. The secondary objective is to evaluate the safety and tolerability of combined administration of entinostat and midazolam in healthy subjects.

Timeline

Start
2017-05-23
Primary completion
2017-06-04
Completion
2017-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule 5 mg Oral
Subject Midazolam Small molecule 2 mg Oral

Indications

No indication recorded.